All patients
Age < 65y (younger) Age > 65y Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), Immune checkpoint association vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.80 [0.61; 1.05]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.79 [0.65; 0.96]
CheckMate 9LA, 2021 0.69 [0.55; 0.87]
KEYNOTE-598, 2020 1.08 [0.85; 1.37]
MYSTIC (DT ; all population), 2020 0.94 [0.80; 1.11]
MYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18]
0.85 [0.75 ; 0.97 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 9LA, 2021, KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 6 45% 3,441 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 9LA, 2021 0.66 [0.55; 0.80]
0.66 [0.55 ; 0.80 ] CheckMate 9LA, 2021 1 0% 719 NA not evaluable PFS (extension)detailed results CheckMate 9LA, 2021 0.68 [0.57; 0.82]
0.68 [0.57 ; 0.82 ] CheckMate 9LA, 2021 1 0% 719 NA not evaluable progression or deaths (PFS)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.77 [0.59; 1.01]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.82 [0.69; 0.97]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.58 [0.41; 0.82]
CheckMate 9LA, 2021 0.70 [0.57; 0.86]
KEYNOTE-598, 2020 1.06 [0.86; 1.30]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53]
0.81 [0.69 ; 0.96 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, KEYNOTE-598, 2020, MYSTIC (DT ; PDL1>25%), 2020 6 64% 2,996 moderate not evaluable objective responses (ORR)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.43 [1.05; 5.65]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.31 [0.97; 1.76]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.26 [1.39; 3.66]
CheckMate 9LA, 2021 1.80 [1.31; 2.48]
KEYNOTE-598, 2020 1.00 [0.72; 1.39]
MYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37]
1.42 [1.05 ; 1.91 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, KEYNOTE-598, 2020, MYSTIC (DT ; PDL1>25%), 2020 6 69% 2,996 moderate not evaluable AE (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.59 [0.20; 1.69]
MYSTIC (DT ; all population), 2020 0.51 [0.27; 0.96]
MYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24]
0.50 [0.31 ; 0.82 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable AE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.70 [0.43; 1.12]
MYSTIC (DT ; all population), 2020 1.02 [0.76; 1.37]
MYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35]
0.91 [0.73 ; 1.13 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable AE leading to death (grade 5)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.41 [0.52; 3.82]
MYSTIC (DT ; all population), 2020 2.19 [1.17; 4.11]
MYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59]
2.19 [1.36 ; 3.51 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.09 [0.58; 2.03]
MYSTIC (DT ; all population), 2020 1.43 [0.97; 2.10]
MYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93]
1.39 [1.05 ; 1.85 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.14 [1.32; 3.47]
2.14 [1.32 ; 3.47 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable SAE (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.76 [1.04; 2.99]
MYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04]
1.86 [1.31 ; 2.62 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 0% 599 moderate not evaluable STRAE (any grade)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.96 [1.36; 2.83]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.67 [1.51; 4.74]
CheckMate 9LA, 2021 1.94 [1.36; 2.76]
MYSTIC (DT ; all population), 2020 1.52 [1.03; 2.24]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87]
1.77 [1.39 ; 2.25 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 5 36% 2,818 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.98 [1.32; 2.98]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.19 [1.14; 4.20]
CheckMate 9LA, 2021 1.95 [1.33; 2.84]
MYSTIC (DT ; all population), 2020 1.43 [0.92; 2.21]
1.83 [1.47 ; 2.28 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 4 0% 2,502 moderate not evaluable TRAE (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.39 [0.22; 0.69]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.66 [0.46; 0.94]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.28 [0.71; 2.30]
CheckMate 9LA, 2021 1.55 [0.94; 2.55]
MYSTIC (DT ; all population), 2020 0.31 [0.22; 0.44]
MYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30]
0.55 [0.29 ; 1.02 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 6 91% 3,101 moderate not evaluable TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.49 [0.29; 0.84]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.96 [0.72; 1.29]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.02 [0.64; 1.65]
CheckMate 9LA, 2021 1.44 [1.06; 1.94]
MYSTIC (DT ; all population), 2020 0.55 [0.39; 0.77]
MYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60]
0.74 [0.49 ; 1.11 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 6 85% 3,101 moderate not evaluable TRAE leading to death (grade 5)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.28; 3.45]
CheckMate 9LA, 2021 1.14 [0.38; 3.43]
MYSTIC (DT ; all population), 2020 1.91 [0.47; 7.71]
MYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13]
1.20 [0.61 ; 2.36 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 5 0% 2,807 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.81 [0.81; 4.05]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.13 [1.95; 5.03]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 3.49 [1.78; 6.83]
CheckMate 9LA, 2021 3.18 [1.94; 5.19]
MYSTIC (DT ; all population), 2020 1.47 [0.92; 2.35]
MYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03]
2.18 [1.47 ; 3.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 6 64% 3,101 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 5.13 [2.63; 10.00]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.90 [1.32; 6.37]
CheckMate 9LA, 2021 3.48 [2.00; 6.05]
MYSTIC (DT ; all population), 2020 2.95 [1.51; 5.78]
3.56 [2.57 ; 4.94 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 4 0% 2,502 moderate not evaluable Acute kidney injury TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 9LA, 2021 7.88 [0.41; 149.53]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
4.26 [0.71 ; 25.42 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 3 0% 1,713 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Anaemia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.21 [0.02; 2.02]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.11 [0.04; 0.28]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.26 [0.07; 0.92]
CheckMate 9LA, 2021 0.37 [0.22; 0.63]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.18 [0.08 ; 0.42 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 59% 2,785 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 1.24 [0.33; 4.65]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.23; 5.95]
CheckMate 9LA, 2021 0.36 [0.09; 1.37]
MYSTIC (DT ; all population), 2020 0.06 [0.00; 1.01]
0.64 [0.26 ; 1.57 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 21% 2,785 moderate not evaluable Colitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 3.86 [0.19; 77.90]
CheckMate 9LA, 2021 9.87 [0.54; 181.39]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
8.18 [1.51 ; 44.34 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 3 0% 1,713 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.02; 50.01]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.59 [0.02; 17.65]
CheckMate 9LA, 2021 0.97 [0.02; 49.27]
MYSTIC (DT ; all population), 2020 0.47 [0.02; 14.16]
0.69 [0.11 ; 4.24 ] CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 4 0% 2,502 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.09; 4.55]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.25; 3.99]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62]
CheckMate 9LA, 2021 0.97 [0.24; 3.93]
MYSTIC (DT ; all population), 2020 0.95 [0.24; 3.82]
0.81 [0.40 ; 1.64 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 0% 2,785 moderate serious Diabetes TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.90 [0.06 ; 56.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 3.24 [0.37; 28.15]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.00 [0.60; 14.96]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.78 [0.29; 10.84]
CheckMate 9LA, 2021 7.06 [1.59; 31.30]
MYSTIC (DT ; all population), 2020 4.35 [0.93; 20.28]
3.76 [1.78 ; 7.94 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 0% 2,785 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33]
2.56 [0.11 ; 57.33 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.47 [0.10; 2.13]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 2.00 [0.60; 6.70]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62]
CheckMate 9LA, 2021 3.97 [0.84; 18.81]
MYSTIC (DT ; all population), 2020 1.09 [0.39; 3.03]
1.18 [0.54 ; 2.58 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 34% 2,785 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.38 [0.60; 3.15]
1.38 [0.60 ; 3.15 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.92 [0.20; 18.73]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
4.15 [0.64 ; 26.90 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 8% 1,006 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Hypertension TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.11; 14.23]
1.27 [0.11 ; 14.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.19 [0.09 ; 15.52 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.56 [0.14 ; 17.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.02; 59.79]
CheckMate 9LA, 2021 1.95 [0.07; 58.39]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
2.04 [0.36 ; 11.70 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 4 0% 2,007 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.04; 10.24]
CheckMate 9LA, 2021 2.46 [0.47; 12.75]
1.73 [0.42 ; 7.13 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 9LA, 2021 2 0% 990 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 9LA, 2021 7.55 [2.24; 25.47]
4.56 [0.64 ; 32.21 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 9LA, 2021 2 28% 990 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.10 [0.01; 2.08]
0.10 [0.01 ; 2.08 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 4.93 [0.57; 42.41]
4.93 [0.57 ; 42.41 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Myositis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Nausea TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.28 [0.06; 1.35]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.16; 8.49]
CheckMate 9LA, 2021 1.63 [0.39; 6.89]
MYSTIC (DT ; all population), 2020 0.16 [0.02; 1.30]
0.61 [0.24 ; 1.55 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 16% 2,785 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.03 [0.00; 0.45]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.01 [0.00; 0.23]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.03 [0.00; 0.46]
CheckMate 9LA, 2021 0.71 [0.41; 1.24]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.20]
0.05 [0.00 ; 0.46 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 82% 2,785 moderate serious Pancreatitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33]
2.56 [0.11 ; 57.33 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 6.52 [0.35; 120.50]
MYSTIC (DT ; all population), 2020 7.74 [0.96; 62.17]
7.30 [1.34 ; 39.79 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Pruritus TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 3.97 [0.18; 88.42]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 4.77 [0.21; 106.62]
CheckMate 9LA, 2021 5.89 [0.29; 118.02]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
2.85 [0.64 ; 12.68 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 0% 2,785 moderate serious Pyrexia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50]
0.32 [0.01 ; 9.50 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Rash TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.31 [0.03; 3.50]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 18.21 [1.05; 315.26]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 7.20 [0.36; 145.12]
CheckMate 9LA, 2021 11.88 [0.66; 213.53]
MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
3.04 [0.61 ; 15.20 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 41% 2,785 moderate serious Stomatitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.16 [0.01; 3.50]
CheckMate 9LA, 2021 1.09 [0.44; 2.70]
MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.22 [0.02 ; 2.51 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 3 72% 1,713 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Vomiting TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50]
CheckMate 227 (NI vs C ; PDL1>1%), 2018 0.10 [0.01; 0.76]
CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.19 [0.02; 1.60]
CheckMate 9LA, 2021 1.17 [0.35; 3.88]
MYSTIC (DT ; all population), 2020 0.07 [0.00; 1.18]
0.28 [0.08 ; 0.98 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 5 42% 2,785 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Alopecia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.14 [0.41; 3.20]
MYSTIC (DT ; all population), 2020 0.12 [0.05; 0.28]
0.36 [0.04 ; 3.34 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 91% 1,286 moderate not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.01 [0.36; 11.05]
2.01 [0.36 ; 11.05 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.25 [0.03; 2.22]
MYSTIC (DT ; all population), 2020 0.86 [0.36; 2.05]
0.70 [0.29 ; 1.72 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 7% 1,286 moderate not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.50 [0.04; 5.51]
MYSTIC (DT ; all population), 2020 0.63 [0.10; 3.80]
0.58 [0.14 ; 2.44 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 0% 1,286 moderate not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.00 [0.14; 7.12]
MYSTIC (DT ; all population), 2020 1.90 [0.17; 21.07]
1.29 [0.28 ; 5.92 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 0% 1,286 low not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.50 [0.02; 14.89]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.66 [0.05 ; 8.56 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 0% 1,286 low not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-598, 2020 6.03 [0.30; 120.98]
MYSTIC (DT ; all population), 2020 1.43 [0.40; 5.11]
1.78 [0.55 ; 5.75 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 0% 1,286 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-598, 2020 10.29 [1.31; 80.96]
MYSTIC (DT ; all population), 2020 2.12 [0.73; 6.17]
3.61 [0.84 ; 15.63 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 44% 1,286 moderate not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.87 [0.31; 2.43]
MYSTIC (DT ; all population), 2020 1.11 [0.37; 3.33]
0.97 [0.46 ; 2.06 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 0% 1,286 low not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.51 [0.42; 5.39]
MYSTIC (DT ; all population), 2020 1.31 [0.52; 3.31]
1.38 [0.65 ; 2.91 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 0% 1,286 moderate not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.00 [0.06; 16.01]
1.00 [0.06 ; 16.01 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.52 [0.48; 13.09]
2.52 [0.48 ; 13.09 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Increased ALT AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.28 [0.69; 7.50]
2.28 [0.69 ; 7.50 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-598, 2020 4.01 [0.18; 89.26]
MYSTIC (DT ; all population), 2020 0.63 [0.18; 2.25]
0.90 [0.21 ; 3.82 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 15% 1,286 moderate not evaluable Neutropenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.01 [0.00 ; 0.19 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pneumonia AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.36 [0.72; 2.56]
1.36 [0.72 ; 2.56 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pneumonitis AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.21 [0.83; 5.91]
2.21 [0.83 ; 5.91 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pruritus AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.50 [0.04; 5.51]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.59 [0.08 ; 4.61 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 0% 1,286 low not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-598, 2020 6.03 [0.30; 120.98]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
3.05 [0.28 ; 33.02 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 0% 1,286 low not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-598, 2020 16.38 [0.94; 286.59]
MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
3.86 [0.24 ; 62.86 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 49% 1,286 moderate not evaluable Thrombocytopenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.03 [0.00 ; 0.42 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-598, 2020 4.03 [0.45; 36.27]
MYSTIC (DT ; all population), 2020 0.13 [0.02; 1.09]
0.72 [0.03 ; 20.37 ] KEYNOTE-598, 2020, MYSTIC (DT ; all population), 2020 2 79% 1,286 moderate not evaluable Weight decreased AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.86 [0.30; 27.64]
2.86 [0.30 ; 27.64 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-15 06:28 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 856,634,861,416,864,769,980
